U.S. jury orders AbbVie to pay $3 million in AndroGel retrial
NEW YORK (Reuters) - A U.S. jury on Monday ordered AbbVie Inc to pay more than $3 million to a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing him to suffer a heart attack, though the jury did not find AbbVie strictly liable.
from Reuters: Health News https://reut.rs/2I2fw91
http://bit.ly/2zwRqiM